Amino acid supplement
L-Citrulline
L-citrulline dose-dependently raised plasma arginine more than oral arginine in a 20-volunteer crossover trial, and that trial could not calculate a half-life; the app lists 1 hour.1
L-Citrulline after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.
Drawn from the half-life in the app's model, ~1 h. The model's figures
- Compound
- L-Citrulline
- Symbol
- CIT
- Family
- Supplements
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
L-citrulline is an amino acid that the app lists as an oral supplement, in the form of the free amino acid or 2:1 citrulline malate. Schwedhelm and colleagues describe it as a non-essential amino acid that "is not subject to presystemic elimination but to systemic metabolism" and that is converted to arginine in two enzyme steps.1 The app grades the evidence as strong. A 2026 meta-analysis of citrulline malate and exercise (Wang and colleagues, Nutrients) reports that "GRADE certainty ranged from low to very low", and its authors declare no conflicts of interest.2 The human trials described below enrolled between 8 and 120 participants.3,4 A query of DailyMed on 16 November 2026 for "citrulline" returned three labels, all multi-ingredient products, and none for L-citrulline alone.
How it works
Sources in this part
Schwedhelm and colleagues state that oral L-arginine "is hampered by extensive presystemic elimination due to intestinal arginase activity", whereas L-citrulline "is readily absorbed and at least in part converted to L-arginine".1 Their reading of the raised blood arginine is that arginine "derived from orally administered l-citrulline is systemically converted to l-arginine, presumably by the kidney and other tissues, including the vasculature".1 Arginine is the substrate for nitric oxide synthase, and the same paper describes nitric oxide as "a vasoactive compound that induces vasodilation of arterial and venous blood vessels".1 In the Citrudose study of 8 healthy men, Moinard and colleagues saw citrulline accumulate at the highest doses, with arginine rising "less than expected", which they attribute to a possible "saturation of the renal conversion of CIT into ARG".3 The app's notes also credit the amino acid with nitric oxide and vasodilation effects; the trials below give mixed results on nitric oxide markers (see "Bloodwork and markers").
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1 h
- Bioavailability
- 80%
- Typical dose
- 6–8 g/dose
- Route
- Oral
- Time to peak
- ~1 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1 h | No half-life figure for citrulline: Schwedhelm and colleagues report that "calculation of half-life was still not possible" even for baseline- and placebo-corrected data; the same paper gives "about 1 h" as the half-life of oral L-arginine, not of citrulline; the IMMUNOCITRE authors refer to "rapid clearance" of administered amino acids and their metabolites in "3 h or less"1,4 |
| Bioavailability | 80% | No absolute oral bioavailability percentage for citrulline in the sources read; Schwedhelm and colleagues call citrulline "readily absorbed", and Moinard and colleagues report urinary citrulline excretion that "remained low" even at high doses1,3 |
| Time to peak | ~1 h | Citrulline Tmax 0.7 ± 0.1, 0.8 ± 0.1 and 0.7 ± 0.1 h at 0.75, 1.5 and 3 g twice daily after 1 week in 20 healthy volunteers (mean ± SEM, baseline-placebo corrected); arginine Tmax 2.3 ± 0.7, 1.6 ± 0.3 and 1.4 ± 0.1 h; in 8 men given single 2 to 15 g doses, arginine reached its maximum at 1.17 (sem 0.26) to 2.29 (sem 0.20) h1,3 |
| Duration of effect | 4 h | Gonzales and colleagues cite a 2016 report by Moinard and colleagues that plasma arginine "returns to basal levels about 5–8 hours after an acute dose of Cit (10g) in older men"; this is a second-hand statement about a different paper5 |
In the same 8-man study, arginine peaked at 146 (sem 8) to 303 (sem 11) micromol/l and ornithine at 81 (sem 4) to 179 (sem 10) micromol/l, depending on the citrulline dose.3
Human studies
Queries of PubMed on 16 November 2026 returned 58 records for citrulline supplementation with plasma arginine and 37 for citrulline malate and exercise performance; the trials below are drawn from them.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Schwedhelm and colleagues, Br J Clin Pharmacol 20081 | Double-blind, randomised, placebo-controlled crossover; sponsored by Angiogenix, a manufacturer of L-citrulline tablets | 20 healthy volunteers (13 male, 7 female) with ADMA in the highest quartile of 168 screened | Citrulline 0.75, 1.5 or 3 g twice daily, arginine 1.0 g three times daily, arginine sustained-release 1.6 g twice daily, or placebo; 7 days each | Citrulline raised plasma arginine AUC and Cmax dose-dependently; at 0.75 g twice daily the AUC change was about as pronounced as with arginine sustained-release 1.6 g twice daily, and the peak was higher than with arginine sustained-release at 1.5 g twice daily; arginine/ADMA ratio 186 ± 8 to 278 ± 14 at 3 g twice daily; no treatment improved flow-mediated vasodilation; no related side-effects1 |
| Moinard and colleagues, Br J Nutr 20083 | Randomised dose-ranging study (Citrudose); funder not named in the record | 8 fasting healthy men | Single doses of 2, 5, 10 and 15 g in random order; blood over 8 h | Arginine and ornithine rose; insulin and growth hormone not affected; no side effects at any dose3 |
| Bailey and colleagues, J Appl Physiol 20156 | Randomised, placebo-controlled crossover; funder not named in the record | 10 healthy men | Citrulline 6 g/day, arginine 6 g/day or placebo; 7 days | Time to exhaustion in severe-intensity cycling 589 ± 101 s on placebo and 661 ± 107 s on citrulline; not altered by arginine6 |
| Suzuki and colleagues, J Int Soc Sports Nutr 20167 | Double-blind, randomised, placebo-controlled crossover; funded by Kyowa Hakko Bio, which employs three authors | 22 trained men analysed (25 enrolled, 3 excluded for colds) | Citrulline 2.4 g/day for 7 days, then 2.4 g 1 h before a 4-km cycling time trial | Completion time 578 ± 15 s on placebo and 569 ± 14 s on citrulline (1.5% shorter); plasma NOx not different7 |
| Pérez-Guisado and Jakeman, J Strength Cond Res 20108 | Randomised, double-blind, 2-period crossover; funder not named in the record | 41 men | Citrulline malate 8 g, single dose, before 16 sets of bench press | More repetitions from the third set evaluated; muscle soreness 40% lower at 24 and 48 h; stomach discomfort in 14.63%8 |
| Gonzales and colleagues, Exp Physiol 20175 | Randomised, double-blind crossover; American Heart Association grant | 25 older adults (13 women, 12 men) | Citrulline 6 g/day or placebo (maltodextrin); 14 days | Arginine up 30% (women) and 35% (men); exercise blood flow higher in men only, and not after adjusting for baseline diastolic pressure; plasma NOx unchanged5 |
| Figueroa and colleagues, Nutrients 20259 | Randomised, placebo-controlled, double-blind crossover with an 8-week washout; no external funding | 22 people with type 2 diabetes initially randomised; 16 completed both periods, 9 female | Citrulline 6 g/day or placebo; 4 weeks each | Reactive hyperemia index, muscle reactivity, plasma arginine and calf strength higher than on placebo; handgrip increase not statistically significant (p = 0.09)9 |
| Tadié and colleagues, IMMUNOCITRE, Crit Care 20234 | Randomised, double-blind, multicentre; French Ministry of Health grant | 120 mechanically ventilated adults in four ICUs, without sepsis or septic shock | Enteral citrulline 5 g every 12 h for 5 days or placebo | SOFA score on day 7 was 4 in both groups; plasma arginine higher on day 3; serious adverse events 13 (23%) against 15 (25%); no difference in plasma arginine between groups on day 7 discussed by the authors4 |
| Esen and colleagues, Int J Environ Res Public Health 202210 | Double-blind, randomised, three groups; no external funding | 15 trained swimmers and triathletes (5 female), 5 per group | Citrulline 8 g/day, arginine 8 g/day or placebo; 8 days | No significant difference in 200 m (p = 0.226) or 100 m (p = 0.993) swim times between groups10 |
| Wang and colleagues, Nutrients 2026 (meta-analysis of citrulline malate)2 | Systematic review and three-level meta-analysis; no external funding | 30 randomised trials, 644 participants | Varied by trial | Small improvement in overall exercise performance (g = 0.16, p = 0.01); perceived exertion not significantly changed; certainty low to very low2 |
Deeper analysis: Schwedhelm and colleagues, oral citrulline and arginine (2008)
Schwedhelm and colleagues, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Centre Hamburg-Eppendorf, reported a randomised, double-blind, placebo-controlled crossover study in the British Journal of Clinical Pharmacology in 2008.1 Volunteers were eligible "if they had ADMA concentrations within the highest quartile of the distribution of the screened population", and all were "apparently healthy White nonsmokers".1 Citrulline at 0.75 g twice daily changed arginine AUC "about as pronounced" as arginine sustained-release at twice that dose, and the peak arginine concentration was higher with citrulline 1.5 g twice daily than with arginine sustained-release.1 The arginine/ADMA ratio rose with citrulline 3 g twice daily and with arginine sustained-release, and the authors state that "Other treatments were ineffective".1 Urinary nitrate and cGMP rose only at the highest citrulline dose, and no treatment improved flow-mediated vasodilation over baseline.1 Of the vascular result the authors write "Although disappointing, this was only a secondary goal of the present study", and they note that endothelial function in their volunteers was normal at baseline.1 They call their results a "rationale for larger, prospective clinical studies with longer treatment periods", and they flag patients "with elevated l-citrulline concentrations, e.g. renal failure" as a group in which side effects remain to be examined.1 The study "was supported by Angiogenix Inc."; its chief medical officer, William Spickler, is a listed author, and Rainer Böger "has received funds for research and fees for consulting from Angiogenix, Inc. a manufacturer of l-citrulline tablets".1
Deeper analysis: Moinard and colleagues, the Citrudose study (2008)
Moinard and colleagues write that citrulline's "pharmacokinetic characteristics and tolerance to loading have not been studied to date", and report 8 fasting healthy men given 2, 5, 10 and 15 g in random order on four occasions.3 Only citrulline, ornithine and arginine concentrations among the plasma amino acids were affected, and insulin and growth hormone were not.3 The authors state that "None of the subjects experienced side effects whatever the CIT dose" and conclude that "Short-term CIT administration is safe and well-tolerated".3 The record is an abridged PubMed entry: it lists the type "Research Support, Non-U.S. Gov't" and does not name a funder, state limitations or give author ties.3
Deeper analysis: Bailey and colleagues, citrulline against arginine (2015)
Bailey and colleagues (University of Exeter) report that plasma arginine rose "by a similar magnitude" with citrulline and arginine, and the PubMed record does not state the funder, author ties or limitations.6
Deeper analysis: Suzuki and colleagues, 4-km cycling time trial (2016)
Suzuki and colleagues reported in the Journal of the International Society of Sports Nutrition in 2016 a double-blind, randomised, placebo-controlled, two-way crossover study in trained Japanese men aged 20 to 39, 22 of whom were analysed.7 Participants took 2.4 g/day of citrulline for 7 days and 2.4 g again 1 h before a 4-km cycling time trial on day 8.7 Completion time fell by 1.5% and mean power output rose from 189 ± 5 W to 193 ± 5 W, while there was "no significant difference in VO2 response" and no significant difference in plasma NOx.7 Plasma branched-chain amino acids were lower after citrulline, and ratings of muscle fatigue and concentration improved immediately after exercise.7 The authors list limitations: "we did not make the training volumes and diets identical among the subjects", and they write that "an additional, larger-scale study will be needed to verify our findings"; they also write that "we were not able to observe an increase in plasma NOx level".7 The study "was conducted in research funding by KYOWA HAKKO BIO CO., LTD."; three authors (Suzuki, Morita and Kamimura) are employees of that company, and the competing-interests statement says the other co-author declares no conflict.7
Deeper analysis: Gonzales and colleagues, exercise blood flow in older adults (2017)
Gonzales and colleagues (Experimental Physiology, 2017) studied 25 older adults in a randomised, double-blind crossover of citrulline 6 g/day against maltodextrin placebo for 14 days, and analysed women and men separately because of "significant sex-by-condition interactions".5 Plasma arginine rose 30% in women and 35% in men; diastolic pressure fell in men (75 ± 9 to 71 ± 6 mmHg, P = 0.02) and was unchanged in women.5 Exercise blood flow rose at higher workloads in men and was not altered in women, and adjusting for baseline diastolic pressure removed the difference in men.5 Plasma NOx did not change, and the authors write that they "have no evidence that NO production was elevated".5 The authors state that the sample "had no history of cardiovascular disease, thus our results may not translate to clinical populations", that no earlier study allowed a power analysis for the main outcome, and that the size of the change "diminishes the clinical meaningfulness of our results".5 The work "was supported by an American Heart Association Beginning Grant-in-Aid".5
Deeper analysis: Figueroa and colleagues, type 2 diabetes (2025)
Figueroa and colleagues (Texas Tech University; Nutrients, 2025) initially randomised 22 people with type 2 diabetes to citrulline 6 g/day or placebo for 4 weeks each, separated by an 8-week washout; one individual withdrew from each group during the first period and 16 participants completed both periods.9 The authors conclude that citrulline "improves microvascular endothelial function, muscle microvascular reactivity, and calf muscle strength", while "the increase in HGSrel was not statistically significant (p = 0.09)".9 Their stated limitations include that "The sample size was small for evaluating sex differences"; the paper states "This research received no external funding" and the authors declare no conflicts of interest.9 The paper reports that "The supplements were well tolerated with no adverse effects reported, except one, who reported mild stomach discomfort".9
Deeper analysis: Tadié and colleagues, IMMUNOCITRE (2023)
Tadié and colleagues reported in Critical Care in 2023 a randomised, double-blind, multicentre trial in four ICUs in France between September 2016 and February 2019, registered as NCT02864017.4 Of 120 mechanically ventilated adults without sepsis or septic shock, 60 received enteral citrulline 5 g every 12 h for 5 days and 60 received placebo.4 The primary outcome, the SOFA score on day 7, was 4 in both groups; the summary gives p = 0.9 and the results table prints 0.77 for the same comparison.4 Plasma arginine was higher on day 3 with citrulline, and immune markers were unaffected; the authors discuss the lack of difference in plasma arginine on day 7 between the two groups.4 The secondary results showed no significant differences between groups: hospital mortality 13 (22%) against 11 (18%), p = 0.46, and nosocomial infections 8 (13.3%) against 17 (28.3%), p = 0.18.4 Adverse events occurred in 23 (40%) patients on citrulline and 27 (46%) on placebo, with serious adverse events in 13 (23%) and 15 (25%); "None of these adverse events were causally related to the study product".4 The authors list limitations including that "the number of screen failure is high and may cast doubt on the general applicability of our results" and that "the median SOFA score at admission was lower than expected".4 Of 2065 patients screened in the four centres, 120 (6%) fulfilled the enrolment criteria and were randomly assigned.4 The trial was funded by a grant from the French Ministry of Health, and the funder had no role in design, analysis or the manuscript; the study drug was Proteocit from Citrage, and the competing-interests statement lists Luc Cynober as "a shareholder of Citrage Co, member of the Citrage Co Scientific Committee".4
Deeper analysis: Wang and colleagues, citrulline malate and exercise (2026)
Wang and colleagues, with authors at the University of Malaya and several Chinese and Spanish institutions, searched six databases "from inception to August 2025" for randomised trials of citrulline malate and exercise performance.2 They report "a small improvement in overall exercise performance (g = 0.16, p = 0.01)" from 30 trials and 644 participants, and that "The pooled effect on perceived exertion was not statistically significant".2 Subgroup findings for aerobic endurance and short anaerobic tasks "were not robust across sensitivity analyses", and no significant subgroup differences were reported for sex, training status, dosage or timing.2 The authors list limitations including "inconsistent reporting and limited independent verification of citrulline-to-malate ratios or absolute citrulline content", publication bias "in several acute subgroups" and low post hoc power.2 The paper states "This research received no external funding" and declares no conflicts of interest.2
Doses reported in studies and on labels
No label giving a dose for L-citrulline alone was identified in DailyMed on 16 November 2026; the doses below are those given in the trials.
| Study | Dose and route | Length | People and comparator |
|---|---|---|---|
| Moinard 20083 | Single oral doses of 2, 5, 10 and 15 g | One day per dose, in random order | 8 fasting healthy men; no placebo arm stated |
| Schwedhelm 20081 | 0.75, 1.5 or 3 g twice daily, oral | 7 days each, with 1-week washouts | 20 healthy volunteers; placebo and arginine |
| Bailey 20156 | 6 g/day, oral | 7 days | 10 healthy men; placebo and arginine 6 g/day |
| Suzuki 20167 | 2.4 g/day, then 2.4 g 1 h before the time trial, oral | 7 days plus day 8 | 22 trained men; cornstarch placebo |
| Pérez-Guisado 20108 | Citrulline malate 8 g, single dose, oral | One training session | 41 men; placebo crossover |
| Gonzales 20175 | 6 g/day, oral | 14 days | 25 older adults; maltodextrin placebo |
| Tadié 20234 | 5 g every 12 h, enteral | 5 days | 120 ventilated ICU adults; isonitrogenous, isocaloric placebo |
The app's typical dose is 6–8 g per dose.
Side effects reported
Moinard and colleagues report that none of 8 men "experienced side effects whatever the CIT dose" from single doses of 2 to 15 g.3 Schwedhelm and colleagues write that in their 20 healthy volunteers "l-citrulline supplementation was well tolerated and no related side-effects were observed", and that blood urea nitrogen and serum creatinine were not altered.1 In the 41-man bench-press trial of citrulline malate 8 g, "The only side effect reported was a feeling of stomach discomfort in 14.63% of the subjects".8 In the IMMUNOCITRE trial, 38 adverse events occurred in 23 (40%) patients on citrulline and 54 in 27 (46%) on placebo, serious adverse events occurred in 13 (23%) and 15 (25%), and the authors report that none "were causally related to the study product".4 Figueroa and colleagues write that "The supplements were well tolerated with no adverse effects reported, except one, who reported mild stomach discomfort".9 The full texts of the Suzuki, Gonzales and Esen reports do not give an adverse-event count, and the PubMed records for the Bailey and Moinard reports do not either beyond what is quoted above.
Bloodwork and markers
Schwedhelm and colleagues measured the plasma arginine/ADMA ratio, urinary nitrate and cGMP and flow-mediated vasodilation, and report that urinary nitrate and cGMP rose only at 3 g twice daily.1 Plasma NOx did not differ from placebo in Suzuki and colleagues or in Gonzales and colleagues, and plasma nitrite "tended to increase" with citrulline (100 ± 38 nM against 83 ± 25 nM on placebo) in Bailey and colleagues.7,5,6 Insulin and growth hormone were not affected by single citrulline doses of 2 to 15 g in 8 men.3
Regulatory and anti-doping status
Sources in this part
A text query of the WADA 2026 Prohibited List document for "citrulline", "arginine" and "amino acid" returned no match, so the document does not name citrulline; this reports the document's text and is not a WADA ruling on any product.11 The DailyMed query for "citrulline" returned three multi-ingredient labels and none for L-citrulline alone, and no regulator's assessment of L-citrulline was identified in the sources read.
What is not known
Sources in this part
None of the sources gives a measured half-life or an absolute oral bioavailability percentage for citrulline, so the app's figures of 1 hour and 80% have no matching figure from the sources.1 The 2026 meta-analysis states that "Reliable dosing, timing, and target populations have not been established" for citrulline malate.2 The longest supplementation period among the trials described here was 4 weeks per arm (Figueroa and colleagues), so the sources read give no data on longer use.9
Frequently asked questions
What is the half-life of L-citrulline?
How long does L-citrulline take to peak in the blood?
What is the bioavailability of L-citrulline?
Does L-citrulline raise plasma arginine more than arginine does?
In Schwedhelm and colleagues' 20-volunteer crossover trial, citrulline "dose-dependently increased AUC and Cmax of plasma L-arginine concentration more effectively than L-arginine".1 The trial was sponsored by Angiogenix, a manufacturer of L-citrulline tablets, and no treatment improved flow-mediated vasodilation over baseline.1
Is L-citrulline banned by WADA?
The WADA 2026 Prohibited List document contains no match for "citrulline" in a text query, and this is a statement about the document's text, not a WADA ruling.11
Did L-citrulline improve exercise performance in trials?
Results are mixed: a 2026 meta-analysis of citrulline malate trials reports "a small improvement in overall exercise performance (g = 0.16, p = 0.01)" with certainty rated low to very low.2 Suzuki and colleagues reported a 1.5% shorter 4-km cycling time (22 men), while Esen and colleagues reported no significant difference in 200 m or 100 m swimming times (15 athletes).7,10
What side effects were reported in L-citrulline trials?
Moinard and colleagues reported no side effects at single doses of 2 to 15 g in 8 men, and Pérez-Guisado and Jakeman reported stomach discomfort in 14.63% of 41 men given citrulline malate 8 g.3,8 In the 120-patient IMMUNOCITRE trial, serious adverse events occurred in 13 (23%) on citrulline and 15 (25%) on placebo.4
Did L-citrulline change blood pressure in trials?
Guides, tools and comparisons
References
- Schwedhelm E, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008. PMID 17662090
- Wang X, et al. Effects of Citrulline Malate Supplementation on Exercise Performance: A Systematic Review and Three-Level Meta-Analysis. Nutrients 2026. PMID 42356270
- Moinard C, et al. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr 2008. PMID 17953788
- Tadié JM, et al. Enteral citrulline supplementation versus placebo on SOFA score on day 7 in mechanically ventilated critically ill patients: the IMMUNOCITRE randomized clinical trial. Crit Care 2023. PMID 37784110
- Gonzales JU, et al. Does l-citrulline supplementation improve exercise blood flow in older adults? Exp Physiol 2017. PMID 28940638
- Bailey SJ, et al. l-Citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. J Appl Physiol 2015. PMID 26023227
- Suzuki T, et al. Oral L-citrulline supplementation enhances cycling time trial performance in healthy trained men: Double-blind randomized placebo-controlled 2-way crossover study. J Int Soc Sports Nutr 2016. PMID 26900386
- Pérez-Guisado J, et al. Citrulline malate enhances athletic anaerobic performance and relieves muscle soreness. J Strength Cond Res 2010. PMID 20386132
- Figueroa A, et al. Citrulline Supplementation Improves Microvascular Function and Muscle Strength in Middle-Aged and Older Adults with Type 2 Diabetes. Nutrients 2025. PMID 40944179
- Esen O, et al. Eight Days of L-Citrulline or L-Arginine Supplementation Did Not Improve 200-m and 100-m Swimming Time Trials. Int J Environ Res Public Health 2022. PMID 35457330
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list